

The background is a dark navy blue. In the upper-left corner, there are two overlapping geometric shapes: a blue parallelogram and a light green parallelogram. Both shapes are oriented diagonally, with their longer sides running from the top-left towards the bottom-right. The green shape is slightly offset to the right and bottom relative to the blue shape. The word "SEPSIS" is written in a white, sans-serif font, centered horizontally in the right half of the image.

SEPSIS

DEFINITION



1. SUSPECTED / DOCUMENTED INFECTION

Infection is the starting point.



2. ORGAN DYSFUNCTION (SEPSIS)

Acute organ dysfunction caused by the infection.

.....

Defined as:
Increase in SOFA score ≥ 2 points from baseline (if known)



3. SEPTIC SHOCK

Sepsis with persistent circulatory and metabolic abnormalities.

.....



Vasopressor therapy needed to maintain
MAP ≥ 65 mmHg



Serum lactate
 > 2.0 mmol/L despite adequate


Sequential [Sepsis-Related] Organ Failure Assessment (SOFA) Score

System	0	1	2	3	4
Respiration PaO ₂ /FiO ₂ , mmHg (kPa)	≥400 (53.3)	<400 (53.3)	<300 (40)	<200 (26.7) with respiratory support	<100 (13.3) with respiratory support
Coagulation Platelets, x10 ³ /uL	≥150	<150	<100	<50	<20
Liver Bilirubin, mg/dL (umol/L)	<1.2 (20)	1.2 - 1.9 (20 - 32)	2.0 - 5.9 (33 - 101)	6.0 - 11.9 (102 - 204)	>12.0 (204)
Cardiovascular	MAP ≥70mmHg	MAP <70mmHg	Dopamine <5 or Dobutamine (any dose)	Dopamine 5.1 - 15 or Epinephrine ≤0.1 or Norepinephrine ≤0.1	Dopamine >15 or Epinephrine >0.1 or Norepinephrine >0.1
CNS GCS Score	15	13 - 14	10 - 12	6 - 9	<6
Renal Creatinine, mg/dL (umol/L) Urine Output, mL/d	<1.2 (110)	1.2 - 1.9 (110 - 170)	2.0 - 3.4 (171 - 299)	3.5 - 4.9 (300 - 440) <500	>5.0 (440) <200



*Catecholamine Doses = ug/kg/min for at least 1hr

SURVIVING SEPSIS 2026



1 PERFORMANCE IMPROVEMENT PROGRAM FOR SEPSIS CARE

For hospitals and health systems, we **recommend** using a performance improvement program for sepsis, including:

- ✓ ✓ ⊕ ⊕ ⊕ ○ | Screening
- ✓ ✓ ⊕ ○ ○ ○ | Standard operating procedures
- ✓ ✓ ⊕ ⊕ ⊕ ○ | Quality improvement strategies



Remark: Performance improvement programs and quality improvement strategies may vary by setting and in accordance with a hospital/health care system's ability to implement.



2021 STATEMENT

For hospitals and health systems, we **recommend** using a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients and standard operating procedures for treatment.

- ✓ ✓ ⊕ ⊕ ⊕ ○ | Screening
- ✓ ✓ ⊕ ○ ○ ○ | Standard operating procedures



Consistent processes. Better outcomes. Lives saved.



CODE SEPSIS AND SEPSIS HUDDLE

- Newer guidelines suggest the use of a sepsis code and a sepsis huddle protocol following a positive sepsis screening
- Sepsis code is activated when

Suspected infection PLUS one or more of:

Hypotension (SBP <90 mmHg or MAP <65 mmHg) , Lactate ≥ 2 mmol/L (especially ≥ 4 mmol/L) , qSOFA ≥ 2 or evidence of organ dysfunction , Persistent tachycardia or tachypnea , Altered mental status

- Sepsis huddle is multidisciplinary team consisting of Physician ,Nurse , ICU team (if required), Pharmacist , Laboratory staff



SCREENING TOOL

- In acutely ill hospitalized patients guidelines suggest the use of screening tools such as NEWS, NEWS2, MEWS or SIRS over qSOFA
- qSOFA has a sensitivity of 23%
- NEWS 2 is the best screening tool
- To be used every 4th hourly to assess the condition of the patient

Chart 1: The NEWS scoring system

Physiological parameter	Score						
	3	2	1	0	1	2	3
Respiration rate (per minute)	≤8		9–11	12–20		21–24	≥25
SpO ₂ Scale 1 (%)	≤91	92–93	94–95	≥96			
SpO ₂ Scale 2 (%)	≤83	84–85	86–87	88–92 ≥93 on air	93–94 on oxygen	95–96 on oxygen	≥97 on oxygen
Air or oxygen?		Oxygen		Air			
Systolic blood pressure (mmHg)	≤90	91–100	101–110	111–219			≥220
Pulse (per minute)	≤40		41–50	51–90	91–110	111–130	≥131
Consciousness				Alert			CVPU
Temperature (°C)	≤35.0		35.1–36.0	36.1–38.0	38.1–39.0	≥39.1	

SEPSIS BUNDLE


- Lactate
- Blood cultures
- Urine output

- Antibiotics
- Crystalloids
- Vasopressors

Hour-1 Bundle

Initial Resuscitation for Sepsis and Septic Shock

Surviving Sepsis Campaign





LACTATE

- Lactate level should be calculated in the first hour itself
- It is a marker of tissue hypoperfusion
- $>2\text{mmol/L}$ - hypoperfusion
- $>4\text{mmol/L}$ - shock
- better predictor of severe sepsis and septic shock than white blood cell count, neutrophil count, and procalcitonin



BLOOD CULTURE

- at least 2 sets of blood cultures should be drawn (aerobic & anaerobic).
- Blood cultures should be drawn from 2 separate peripheral sites
- if the patient has an indwelling central catheter that is suspected to be infected, cultures should be performed through each lumen of the catheter, in addition to the peripheral site.
- blood cultures should be obtained prior to the initiation of antibiotics



INFECTION

- Septic shock or sepsis - antibiotics within 1hr
- Possible sepsis - within 3hrs
- If there is a delay in transfer of patient for more than 1hour antibiotics should be administered in ambulance
- Anatomical or source diagnosis within 6 hrs

INFECTION MANAGEMENT IN SEPSIS

Key Principles



EARLY ANTIBIOTICS

- Septic shock or sepsis – antibiotics within 1 hr
- Possible sepsis – within 3 hrs
- If delay in transfer >1 hr – give antibiotics in ambulance



SOURCE CONTROL

- Anatomical or source diagnosis within 6 hrs
- Drain abscess, remove infected lines, debride, relieve obstruction



RISK STRATIFICATION


- If high risk of MDR pathogen – use antimicrobial with MDR coverage
- No risk of anaerobic infection – anaerobic coverage not indicated
- Empirical antifungal not indicated in low-risk patients



REASSESSMENT

- Review daily and narrow therapy when possible
- De-escalate based on culture, sensitivity or alternate diagnosis

EMPIRICAL ANTIBIOTIC THERAPY – APPROACH



Site of infection	Potential bacteria	%	Suggested empirical treatment
 Urinary tract infections (severe acute pyelonephritis)	Enterobacteriaceae including: <i>Escherichia coli</i> <i>Pseudomonas aeruginosa</i> <i>Enterococcus sp.</i> <i>Staphylococcus sp.</i>	60–70 40 8 15 4	Ceftriaxone IV or ceftazidime (if suspicion of <i>P. aeruginosa</i>) ± aminoglycoside
 Intra-abdominal sepsis	Gram-negative bacilli including: <i>Escherichia coli</i> <i>Pseudomonas aeruginosa</i>	60 40 30	Ertapenem (if no risk of <i>P. aeruginosa</i>) Piperacillin–tazobactam
	Gram-positive cocci including: <i>Enterococcus sp.</i> - Anaerobes including <i>Bacteroides sp.</i> - Fungi	30 20 30 20 20	Third- or fourth-generation cephalosporin (active against <i>P. aeruginosa</i>) + metronidazole Imipenem or doripenem (high-risk patients) ± fluconazole ± aminoglycoside (if shocked)
 Nosocomial pneumonia	<i>Enterobacteriaceae</i> <i>Pseudomonas aeruginosa</i> <i>Staphylococcus aureus</i> <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i>	30–40 17–30 7–15 3–5 4–6	β-lactam (active against <i>P. aeruginosa</i>) ± aminoglycoside ± glycopeptide or linezolid if MRSA is suspected



Pneumonia without risk factors for MRP

- *Staphylococcus aureus*
- *Streptococcus pneumoniae*
- *Haemophilus influenzae*
- Alternative Gram-negative bacilli
- Anaerobes

45
9
20
20
4

Third-generation cephalosporin
without activity against *P. aeruginosa*
± Macrolide (if intracellular
bacteria are suspected)



Skin infections

- *Streptococcus* sp.
- *Staphylococcus* sp.
- Anaerobes
- Gram-negative bacilli

40
30
30
10–20

β-lactam + β-lactamase inhibitor
Piperacillin/tazobactam
Second-generation cephalosporins
(such as cefoxitin)
Carbapenems



Catheter-related bloodstream infection

- *Staphylococcus* sp.
- *Enterobacteriaceae*
- *Pseudomonas aeruginosa*

50
30
10–15

Glycopeptide or linezolid + β-lactam
with activity against *P. aeruginosa*



Nosocomial meningitis

- Gram-negative bacilli including
Acinetobacter sp.
- *Staphylococcus* sp.
 - *Streptococcus* sp.
 - *Neisseria meningitidis*

60
30
20
10
1

Meropenem + glycopeptide
or linezolid

ONGOING MANAGEMENT & OPTIMIZATION



Beta-lactam infusions preferred over bolus for maintenance therapy
TDM (Therapeutic Drug Monitoring) should be used



De-escalation to narrow spectrum (antigen specific) when
microbiological diagnosis / susceptibility or alternate diagnosis obtained



If optimal duration is unclear – PCT + clinical evaluation can be used
for de-escalation



Consider SDD (Selective Digestive Decontamination) in septic
patients on mechanical ventilation (as per ICU policy)



Candidal biomarkers should NOT be used to guide initiation
or de-escalation of antifungal therapy



DURATION OF THERAPY (Usual Guidance)

- Uncomplicated infections:
7–10 days
- With adequate source
control: 5–7 days
- Complicated / deep-seated /
immunocompromised:
10–14 days or more
- Reassess daily and stop
when infection controlled



PEARLS

- Early antibiotics save lives
- Source control is as important
as antibiotics
- Reassess daily and de-escalate
whenever possible
- Use local antibiogram and
stewardship principles

1**START EMPIRIC BROAD-SPECTRUM ANTIBIOTICS**

- Within 1 hour in septic shock
- After obtaining cultures (do not delay >45 min)

**2****OBTAIN MICROBIOLOGICAL CULTURES**

- Blood cultures x 2 (from different sites)
- Source-specific cultures (urine, sputum, pus, CSF, body fluids, etc.)

**3****REASSESS AT 48–72 HOURS
("ANTIBIOTIC TIME-OUT")**

- | | |
|---|---|
| ☒ Clinical improvement? | ☒ Organ function improving? |
| ☒ Hemodynamics stable? | ☒ Culture & susceptibility results? |
| | ☒ Source control achieved? |
| | ☒ Biomarkers (PCT/CRP) ↓? |

YES

(Improving)

**4****DE-ESCALATE (WHEN APPROPRIATE)****Narrow spectrum
(targeted therapy)****Stop combination therapy
(use single active agent)****IV to Oral switch
(if clinically stable & able to absorb)****Shorten duration
(use shortest effective duration)****NO**

(Not improving / Unstable)

**4****CONTINUE / MODIFY THERAPY****Continue current broad-spectrum
therapy****Reassess for:**

- Inadequate source control
- Wrong/ Resistant pathogen
- Complications / New focus
- Drug dosing / PK–PD issues

**Consider ID consultation**

ANTIFUNGALS IN SEPSIS

- Empirical antifungal should not be given in patient with low risk of fungal infection
- When to consider

HIGH-RISK FEATURES (Consider Empirical Antifungal Therapy)			
 Recent abdominal surgery or GI perforation	 Necrotizing pancreatitis	 Prolonged ICU stay	 Broad-spectrum antibiotic exposure
 Total parenteral nutrition (TPN)	 Central venous catheter	 Immunosuppression / neutropenia	 Previous Candida colonization

- Candidal biomarkers should not be used to guide neither initiation nor deescalation of antifungal therapy



FLUID RESUSCITATION

- Initial target 30ml/kg in 3hrs (should be individualised)
- Reassessment should be done after each bolus dose
- Maintenance fluid , if oral intake is poor - 1-1.5ml/kg/hr
- Reassess after every bolus dose

- 
- Dynamic measures to guide fluid resuscitation over static and physical measures.

1. Stroke volume

2. Stroke volume variation

3. Pulse pressure

4. Pulse pressure variation

- Serial lactate measures can be used to guide fluid resuscitation in patients with septic shock
- Capillary refill time can also be used in septic shock



END POINT OF RESUSCITATION

Stop fluids when any of the 3 met :

1. CVP - 8-12mmHg
2. IVC collapse with <50% with breathing
3. Passive leg raise = no BP increase




PREFERRED FLUIDS

- Bp monitoring - either invasive or non invasive
- Fluid - balanced crystalloids > normal saline

Balanced crystalloids > balanced crystalloids with albumin

- Albumin can be considered in patients who has already received large amount of crystalloids
- Avoid starch and gelatin
- Fluid resuscitation after initial bolus of 30ml/kg , should be personalized according to the patient factors





Respiratory support

- Measurement of oxygenation : ABG > Pulsoximeter
- Target SpO₂ - 90% - 96%
- Sepsis patient with acute hypoxemic respiratory failure HFNC preferred over NIPPV
- Awake proning - non intubated patients
- Sepsis with ARDS

Tidal volume - 6ml/kg (low TV)

PEEP - High

Plateau pressure of 30cmH₂O

Prone ventilation > 12hrs



ADJUNCTIVE THERAPIES

- Corticosteroids are used in pressor refractory shock - >4hrs
 - Hydrocortisone 200mg/day
 - Not used in sepsis
 - ADRENAL or APROCCHSS TRIAL
-
- Not recommended

VIT C / ivig / hemoperfusion/ PLEx / VIT D



STRESS ULCER PROPHYLAXIS

- Prophylaxis should be given for patients high risk of GI bleeding
- High risk factors
 1. Coagulopathy
 2. Cirrhosis / CLD
 3. Shock
- Mechanical ventilation alone is not considered as a major risk factor for GI bleeding
- Other factors include : AKI / Uremia / TBI / high dose corticosteroids



NUTRITION IN SEPSIS

- Early initiation of enteral nutrition within 72hrs
- NG / OG Tube is the preferred mode
- Post pyloric feeding is considered if high risk of aspiration
- Calorie : 25-30Kcal/kg/day
- Protein : 1.2-2g/kg/day



GLYCEMIC CONTROL

- Blood glucose should be maintained in between 140-180mg/dl
- According to NICE - SUGAR trial : a tight glycemc control will increase the mortality
- Use insulin if glucose >180mg/dl
- Avoid hypoglycaemia <70
- Loose control is better than tight control
-



ANEMIA

- No routine transfusion is indicated if Hb >7g/dl
- Transfuse symptomatic anemia
- REALITY Trial

